Comparative Pharmacology
Head-to-head clinical analysis: ADAGEN versus BRINEURA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADAGEN versus BRINEURA.
ADAGEN vs BRINEURA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ADAGEN (pegademase bovine) is a modified form of the enzyme adenosine deaminase (ADA). It catalyzes the deamination of adenosine and 2'-deoxyadenosine to inosine and 2'-deoxyinosine, respectively, thereby reducing the accumulation of toxic metabolites (deoxyadenosine triphosphate) that cause lymphotoxicity in patients with severe combined immunodeficiency disease (SCID) due to ADA deficiency.
BRINEURA (cerliponase alfa) is a recombinant human tripeptidyl peptidase-1 (TPP1) enzyme that replaces deficient TPP1 in patients with neuronal ceroid lipofuscinosis type 2 (CLN2 disease). It hydrolyzes tripeptides from the N-terminus of proteins, reducing accumulation of autofluorescent lipopigments in lysosomes.
30 U/kg intramuscularly or subcutaneously once weekly; adjust dose based on adenosine deaminase (ADA) activity and clinical response.
400 mg every 2 weeks via intravenous infusion over 1.5 hours.
None Documented
None Documented
Terminal elimination half-life is approximately 3-6 days (mean ~3.5 days) in patients with ADA-SCID, allowing for weekly intramuscular dosing.
Terminal half-life is approximately 3 to 4 days (mean 3.5 days) in pediatric patients, supporting weekly intravenous dosing.
Renal: approximately 40-60% of administered dose as intact polyethylene glycol conjugate; the remainder undergoes enzymatic degradation or biliary excretion. Fecal elimination is minimal.
Primarily catabolized via peptide hydrolysis to small peptides and amino acids; renal excretion of intact enzyme is negligible (<1% of dose).
Category C
Category C
Enzyme Replacement
Enzyme Replacement